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Background: Most antiepileptic drugs (AEDs) inhibit seizure generation by acting on 
voltage-dependent ion channels. Voltage-dependent sodium and calcium channels are 
commonly expressed in brain and heart, suggesting that AEDs may have considerable 
cardiodepressive effects, thereby facilitating sudden cardiac death as a potential cause 
of sudden unexpected death in epilepsy. Here, we investigated the effects of carbamaz-
epine (CBZ), lamotrigine (LTG), and levetiracetam (LEV) alone and in combination on the 
shortening properties of isolated ventricular cardiomyocytes of wild-type mice.
Methods: Properties of murine cardiomyocytes were determined by recording the sar-
comere shortening with a video imaging system before, during, and after administration 
of AEDs in different concentrations and combinations. We assessed (i) the number of 
successful shortenings during continuous electrical stimulation (electromechanical cou-
pling) and (ii) the shortening amplitude as well as other shortening-related properties 
upon repetitive electrical stimulation at 4 Hz. Data are given as mean ± SEM.
results: At 100 µM, CBZ (10 cells), LTG (11 cells), and LEV (11 cells) alone had no 
effect on the electromechanical coupling but reversibly reduced shortening amplitudes 
by 15 ± 4, 24 ± 3, and 11 ± 3%, respectively. Increasing the LTG concentration to 250 
(21 cells) and 500 µM (4 cells) reversibly inhibited the electromechanical coupling in 62 
and 100% of the experiments. Importantly, simultaneous application of CBZ, LTG, and 
LEV at 100 µM also impaired the electromechanical coupling in 8 of 19 cardiomyocytes 
(42%) and reduced the shortening amplitude by 21 ± 4%.
conclusion: Our data show that AEDs reversibly impair cardiac excitation and con-
traction. Importantly, the blocking effect on electromechanical coupling appears to be 
additive when different AEDs are simultaneously applied. The translational value of these 
experimental findings into clinical practice is limited. Our results, however, suggest that 
rationale AED therapy may be important with respect to cardiac side effects and potential 
facilitation of serious cardiac dysfunction especially when AEDs are used in combination 
or at very high doses.
Keywords: antiepileptic drugs, cardiac block, cardiomyocytes, contraction, epilepsy, side effects, sudden 
unexpected death in epilepsy
2Hulbert et al. Blocking Effects of AEDs on Cardiomyocytes
Frontiers in Neurology | www.frontiersin.org April 2017 | Volume 8 | Article 133
inTrODUcTiOn
In people with epilepsy, the risk of dying prematurely is increased 
2.5-fold as compared to the general population (1), about one 
fifth of these cases are due to sudden unexpected death in epilepsy 
(SUDEP) (2). The MORTEMUS study has shown that the fatal 
event is probably due to a severe suppression of cardiorespira-
tory function shortly after a generalized tonic–clonic seizure in 
the majority of SUDEP cases (3). Given the large spectrum of 
epilepsy-related cardiorespiratory alterations, however, SUDEP is 
likely to be a heterogeneous phenomenon and to have multiple 
causes (4). For instance, SUDEP may also occur in the absence 
of epileptic seizures with a similar pattern as described in the 
MORTEMUS study (5). It is also plausible that, in some cases, 
SUDEP is due to fatal cardiac arrhythmias such as bradyarrhyth-
mias or ventricular tachyarrhythmias that are not directly related 
to epileptic seizures. This assumption is supported by several 
facts: (i) people with epilepsy frequently display abnormal cardiac 
and autonomic features in the absence of epileptic seizures (6), 
(ii) epilepsy is a risk factor for sudden cardiac death in the general 
population (7), (iii) sudden cardiac death occurred in people with 
epilepsy without evidence of precedent epileptic seizures (8), and 
(iv) about 10% of witnessed SUDEP cases were reported without 
apparent seizure activity (9).
The apparent propensity to cardiac mortality and sudden car-
diac death in people with epilepsy may have genetic or acquired, 
epilepsy-related causes. Furthermore, antiepileptic drugs (AEDs) 
appear to be an independent risk factor for sudden cardiac death, 
especially in those patients taking AEDs that target voltage-gated 
sodium channels (VGSC) (10, 11). Numerous experimental stud-
ies have revealed that many AED predominantly act on excitatory 
VGSC and voltage-gated calcium channels (VGCC) or interact 
with ligand-gated chloride- and mixed-cation channels. A single 
AED, however, can bind to multiple targets (12, 13). For instance, 
the drugs that are usually considered as “sodium channel block-
ers” such as carbamazepine (CBZ), lamotrigine (LTG), and phe-
nytoin also inhibit high-threshold VGCC, whereas levetiracetam 
(LEV) appears to mediate its antiepileptic effects via binding to 
the presynaptic synaptic vesicle protein 2A but also acts on high-
threshold VGCC (12, 13).
Voltage-gated sodium channels and VGCC are expressed 
both in the brain and heart. The different subtypes of these 
channels, however, display predominant expression patterns, 
e.g., within cerebral or cardiac tissue. For instance, the VGSC 
subtypes NaV1.1, 1.2, 1.3, and 1.6 are primarily responsible for 
neuronal depolarization in the brain, whereas NaV1.4 and 1.5 
are predominantly found in skeletal and cardiac muscle (14). The 
VGCC subtypes CaV1.2 and 1.3 as well as CaV3.1 and 3.2 are 
expressed in neurons and cardiomyocytes (15).
In our study, we wanted to examine the effects on cardiac tis-
sue of three selected AEDs alone and in combination. We have 
chosen CBZ as it is considered the prototype of sodium channel 
blockers used in the treatment of people with epilepsy. LEV and 
LTG were selected, because they are nowadays the most widely 
used AEDs in the developed countries (16). Furthermore, CBZ 
and LTG were discussed as potential risk factors for SUDEP in 
previous studies (17). As a single AED can modulate both VGSC 
and VGCC, we have not investigated effects on a selected molecu-
lar target (e.g., by performing patch-clamp recordings to measure 
specific ion currents) but have recorded the shortening of isolated 
cardiomyocytes upon electrical stimulation. This experimental 
approach does not allow the attribution of the observed effects to 
a specific molecular target but represents the sum of all pathways 
that are involved in the excitation and shortening of cardio-
myocytes. We have assessed electromechanical coupling and the 
shortening properties upon application of CBZ, LTG, and LEV 
alone and in combination.
MaTerials anD MeThODs
animals
C57BL/6 mice of male sex (Charles River/Breeding in the 
Department of Anatomy at the University of Bonn) were housed 
at 22°C with 12-h light–dark cycle and fed with water and food 
ad libitum. Twelve- to sixteen-week-old mice were used for the 
experiments. Animals were anesthetized using isoflurane in 
room air and euthanized by cervical dislocation.
Murine cardiomyocyte isolation
Myocytes were isolated as previously described (18). The hearts 
were removed and transferred to a cold cardioplegic EGTA-
Tyrode solution (NaCl 135 mM, KCl 4 mM, MgCl2 1 mM, HEPES 
2 mM, and EGTA 0.1%, pH 7.4). The removed hearts were rapidly 
attached to a modified Langendorff apparatus and perfused with 
oxygenated and heated solutions (35–36°C). Hearts were firstly 
perfused with EGTA-Tyrode, then with a high-potassium solu-
tion (NaCl 4 mM, KCl 10 mM, MgCl2 1 mM, CaCl2 0.025 mM, 
K-glutamate 130  mM, HEPES 4  mM, glucose monohydrate 
9  mM), followed by high-potassium solution supplemented 
with trypsin (150  U/ml Type I, Sigma-Aldrich) and finally 
by high-potassium solution supplemented with collagenase 
(16  U/ml—caseinase activity—Sigma blend Type L, Sigma-
Aldrich). Afterward, the ventricles were cutoff the Langendorff 
apparatus, finely minced and completely dismantled by stirring 
with a glass bar inside experimental Tyrode [NaCl 135  mM, 
KCl 4 mM, MgCl2 1 mM, CaCl2 1.8 mM, HEPES 2 mM, glucose 
monohydrate 10.1 mM, bovine serum albumin 0.1%, and trypsin 
inhibitor (Type II-S Soybean 1.67 mg/100 ml, pH 7.4)]. The solu-
tion was filtered through a 125-µm nylon mesh and centrifuged 
slowly for about 10 s. The cells were resuspended in fresh solution, 
allowed to settle for 7 min (heating cabinet 36°C) and resuspended 
again. Isolated cells were kept in oxygenated experimental Tyrode 
solution at room temperature for up to 6 h.
sarcomere shortening
For sarcomere length measurement cells were placed in a Laminin 
coated, heated chamber (35–36°C) on an inverted microscope 
(ZeissAxiovert 100 TV, Jena, Germany, lens: Neofluar 40/0.75) 
and continuously perfused with the experimental solutions. 
Sarcomere shortening of isolated ventricular myocytes was 
recorded with a video imaging system (Myocam) and SarcLen 
software (IonOptix; Milton, MA, USA) as previously described 
(Figure 1A) (19). The regular striation pattern of the sarcomeres 
FigUre 1 | setup and time course of experiments. (a) Experimental setup allowing optical measurement of sarcomere lengthening (see Materials and Methods 
for details). (B) A scheme of the time course of experiments. Shortenings were elicited by regular stimulations at 4 Hz before, during, and after wash-out of the test 
solutions. (c) Example of recording traces. The sarcomere length shortens upon extracellular electrical stimulation from about 1.76 to 1.62 µm.
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is analyzed by fast Fourier transformation. Sarcomere shorten-
ing shifts the power spectrum peak, which corresponds to the 
absolute sarcomere length (Figure  1C) (20). Shortenings were 
induced by bipolar external stimuli via two gold electrodes 
(0.4 ms, 40 V, SD9, Grass; Quincy, MA, USA). During the record-
ings, the isolated cardiomyocytes were continuously stimulated 
at a frequency of 4 Hz. After a “run-in period” of about 200 s to 
establish steady-state shortenings with continuous bathing with 
experimental Tyrode, the solution was switched to a drug-con-
taining Tyrode for 3 min. Afterward, the solution was switched 
back to Tyrode solution again for 3 min to show wash-out of the 
drug (Figure 1B).
Drugs
Stock solutions containing CBZ and LTG were dissolved in 
dimethyl sulfoxide (DMSO). LEV was prepared in distilled 
water. Stock solutions were stored at −20°C or prepared freshly 
and added to experimental Tyrode just before use. The final 
experimental concentrations used in our experiments were 
100  µM CBZ, 100, 250, and 500  µM LTG, and 100  µM LEV. 
The concentration of DMSO did not exceed 1:1,000 (1:500 for 
LTG 500 µM). The Tyrode solution used before and after drug 
wash-in (control condition) contained DMSO in corresponding 
concentrations. Drugs and all other chemicals were purchased 
from Sigma-Aldrich (Taufkirchen, Germany).
Data analysis
The evaluation of the cardiomyocyte shortening was carried out 
using IonWizard 6 (IonOptix). Only rod shaped faultless cells 
with a uniform striation pattern were selected for recordings. 
Recordings were included in the final analysis when cardiomyo-
cytes displayed a stable steady state at the point of data acquisition 
and when they survived the recurrent stimulation for the whole 
recording period. To exclude a toxic effect or gradual death of 
the recorded cardiomyocytes, we only included those record-
ings in which the drug effect was reversible. We assessed (i) the 
number of successful shortenings following individual electrical 
stimulations (electromechanical coupling) and (ii) the shortening 
properties (sarcomere length, shortening amplitude, maximal 
shortening velocity, maximal relengthening velocity, and the 
time to return to 90% of the baseline) upon repetitive electrical 
stimulation at 4 Hz before, during, and after application of the 
AEDs.
The shortening velocity (in micrometers per  second) 
characterizes the maximal speed with which the cell shortens. 
The relengthening velocity (in micrometers per  second) is the 
4Hulbert et al. Blocking Effects of AEDs on Cardiomyocytes
Frontiers in Neurology | www.frontiersin.org April 2017 | Volume 8 | Article 133
maximal speed in the return phase of the transient. The time to 
return to 90% of the baseline (in milliseconds) is a measure of 
cellular relaxation. To quantify the shortening properties, we have 
averaged the last 10 shortening signals before wash-in and wash-
out, respectively. For statistical analysis, a repeated-measures 
ANOVA followed by Newman–Keuls corrected post hoc analysis 
was used when appropriate. ANOVA tests were performed using 
GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA, 
USA). p-Value <0.05 was considered as significant (***p < 0.001, 
**p < 0.01, *p < 0.05). All data are given as mean ± SEM.
resUlTs
external ca2+ reversibly Modulates 
shortening amplitudes of isolated 
cardiomyocytes
To explore the recording conditions and the validity of our 
experimental approach, we measured sarcomere shortening at 
three different external calcium concentrations, namely, 1.2, 1.8 
(defined as control condition), and 3.6  mM. As expected, the 
switch from 1.8 to 1.2  mM external Ca2+ reversibly decreased 
the shortening amplitude of the isolated cardiomyocytes by 
46 ±  5% (from 0.073 ±  0.012 μm under control condition to 
0.041 ± 0. 009 µm, p < 0.001, Figure 2A). Conversely, the increase 
of the external Ca2+ concentration from 1.8 to 3.6 µM led to a 
reversible enhancement of the shortening amplitude by 44 ± 5% 
(from 0.093 ± 0.008 to 0.13 ± 0.01 μm, p < 0.0001, Figure 2B).
aeDs reversibly impair shortening 
Properties of isolated cardiomyocytes
First, the effects on the shortening properties of cardiomyocytes 
were tested for each AED separately. All three drugs at a con-
centration of 100 µM did not affect electromechanical coupling 
(i.e., each electrical stimulation induced a shortening) but led 
to a reversible reduction in shortening amplitudes. Original 
recordings of sarcomere lengths and shortenings before, during, 
and after application of LEV are shown in Figure  3A. While 
the depressive effects of CBZ (10 cells) and LEV (11 cells) 
ranged between 11 and 15% (Figures 3A,B; Table 1), LTG (11 
cells) led to a reduction of the shortening amplitude by about 
24% (Figure 3C; Table 1). Furthermore, LTG also reduced the 
shortening velocity by 23 ±  4% and the relengthening velocity 
by 23 ± 5% (Table 1), whereas CBZ and LEV did not affect the 
shortening and relengthening velocities at the given concentra-
tion. The time of return to 90% of the baseline was not affected 
by any of the tested drugs.
As 100 µM LTG appeared to have the greatest impact on car-
diomyocytes, we have also explored the effects of LTG at higher 
concentrations (250 and 500 µM). Interestingly, during application 
of LTG at 250 (21 cells) and 500 µM (4 cells), a variable proportion 
of the cardiomyocytes failed to shorten in response to every single 
electrical stimulation (for original traces see Figure  4A). The 
number of the failed shortenings increased with increasing time 
of application. At 250 and 500 µM LTG, the electromechanical 
coupling was irregular in 62 and 100% of the cells, respectively 
(Figure 4B). The shortening amplitudes after a failed excitation 
in 500 µM LTG were higher than those under control conditions, 
because murine cardiomyocytes develop an increased post-rest 
shortening after a stimulation pause compared to the steady state.
effect of simultaneously applied aeDs on 
electromechanical coupling
So far, we have applied the AEDs separately. In clinical practice, 
however, people with epilepsy often take more than one AED to 
achieve better seizure control. Therefore, CBZ, LTG, and LEV 
were simultaneously applied at a concentration of 100 µM each, 
i.e., at the same concentration as compared to the abovementioned 
experiments when each AED was applied alone. The combination 
of all three drugs led to electromechanical coupling failure in 
eight cells (42% of all recordings, Figure 4C). In the 11 cells with 
undisturbed coupling, effects on the shortening properties of the 
simultaneous drug application could be properly determined. 
The shortening amplitude was inhibited by 21 ± 4% (Figure 4C), 
the shortening and relengthening velocities were reduced by 
23 ± 3 and 18 ± 5%, respectively (Table 1).
To further characterize the blocking effects on the electro-
mechanical coupling, we have quantified the number of failed 
stimulations (i.e., no shortening) with respect to the total number 
of electrical stimulations for those cells that showed a disturbed 
electromechanical coupling. The failure rate amounted to 
49 ± 11% upon simultaneous application of CBZ, LEV, and LTG 
(i.e., every second stimulation failed to evoke a shortening) and 
was even higher during application of very high LTG concentra-
tions (Figure 5C).
DiscUssiOn
Depressed cardiac shortening: 
Mechanisms of action and Possible 
clinical implications
All three AEDs alone reversibly reduced the shortening ampli-
tudes of isolated cardiomyocytes (Figure 5A). Our study was not 
designed to investigate the mechanisms that are involved in the 
modulation of shortening properties of isolated cardiomyocytes. 
In the case of CBZ and LTG, however, the well-described inhibi-
tory effects on VGSC and VGCC most likely underlie the observed 
depressive action of CBZ and LTG (12, 13). CBZ and LTG at 
100 µM reduced the shortening amplitudes by about 15 and 24%, 
respectively. It is difficult to translate the extent and importance 
of these in  vitro findings into clinical practice for at least two 
reasons: first, we have applied relatively high concentrations 
of CBZ and LTG as compared to the typical therapeutic serum 
levels in epilepsy patients (LTG 12–58 µM, CBZ 17–51 µM) (21). 
Second, the inhibitory effects of CBZ and LTG on VCSC are use 
dependent, i.e., the inhibition gets stronger with increasing stimu-
lation frequencies (22, 23). In our experiments, the cardiomyo-
cytes were stimulated at 4 Hz only, as the recordings were stable 
for at least 10–15 min at this particular frequency. This stimula-
tion frequency equals a heart rate of 240 beats per minute, which 
is low as compared to the habitual resting heart rate between 500 
and 600 beats per minute in mice, but still much higher than the 
resting heart rate in adult humans. Thus, the effect size of CBZ or 
FigUre 2 | Modulation of sarcomere shortening properties by external calcium. (a) Lowering of external calcium to 1.2 mM reversibly impaired shortening 
amplitudes. Left panel shows recording traces before, during, and after switch to external solution containing 1.2 mM. The results of six recordings are summarized 
as bar charts in the right panel. (B) Increasing external calcium to 3.6 mM reversibly enhanced shortening amplitudes. Left panel shows recording traces before, 
during, and after switch to external solution containing 3.6 mM Ca2+. The results of 12 recordings are summarized as bar charts in the right panel. Both the 
Ca2+-dependent reduction and the respective increase in shortening are highly significant.
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LTG on cardiac contraction at typical therapeutic concentrations 
is likely to be lower in epilepsy patients. In the instance of a CBZ 
or LTG overdose, however, the inhibitory effects on contraction 
properties as well as on electromechanical coupling (as shown 
at 250 and 500 µM LTG) appear to be of clinical importance, as 
illustrated by previous case reports (24, 25).
Levetiracetam at 100  µM reversibly reduced the shortening 
amplitude by about 11%. This depressive LEV effect was rather 
unexpected but can be explained by its inhibitory action on 
voltage-gated L-type calcium channels (26, 27). Although the 
concentration of LEV was well within the typical serum levels of 
epilepsy patients (70–270 µM) (21), the cardiodepressive effect is 
small and unlikely to be clinically significant, given the fact that 
rapid intravenous infusion of LEV had no apparent cardiovascu-
lar effects in healthy controls and epilepsy patients (28, 29).
Faulty electromechanical coupling: 
Mechanisms of action and Possible 
clinical implications
Electromechanical coupling was reversibly blocked only at very 
high concentrations of LTG or when all three AEDs at 100 µM 
were simultaneously applied (Figures 5B,C). In our experimental 
constellation, this phenomenon may be due to an inhibition of 
cellular excitation, of the excitation–shortening coupling, the 
shortening itself, or a combination of these elements, probably 
via binding to VGSC and VGCC.
In our point of view, the effect of the simultaneous applica-
tion of the AEDS is particularly important in the clinical context. 
About one-third of the epilepsy patients are difficult to treat, i.e., 
they commonly need more than one AED to achieve better or 
full seizure control (30). Polypharmacy, in turn, was suspected 
to increase the risk of SUDEP (31). Subsequent studies have 
finally revealed that polypharmacy is not a risk factor itself, but 
rather a surrogate marker of severe epilepsy and insufficient 
seizure control (32) and that efficacious adjunctive AED treat-
ment reduces the SUDEP risk (33). It appears, however, plausible 
that simultaneous administration of AEDs that bind to the same 
cellular targets increases the risk of target-related side effects. 
Therefore, it is not surprising that cardiac side effects such as 
atrioventricular block, sinus node dysfunction, or arrhythmo-
genic ST–T abnormalities were reported in the context of simul-
taneous intake of AED that inhibits VGSC (34–36). We think that 
cardiac side effects can indeed, if long lasting and severe enough, 
facilitate sudden cardiac death as a rare cause of SUDEP in some 
epilepsy patients. This view is also supported by the finding that 
AED intake is an independent risk factor for sudden cardiac 
death (10, 11). In this context, it is of note that CBZ and LTG 
were discussed as potential risk factors for SUDEP in previous 
studies (17). However, these assumptions could not be replicated 
in subsequent meta-analyses or when studies were adjusted for 
the frequency of generalized tonic–clonic seizures (17, 32, 37). To 
date, no single AED has unequivocally been proven to increase 
the SUDEP risk.
TaBle 1 | absolute effects of antiepileptic drugs on shortening properties.
lamotrigine 100 µM  
(n = 11)
carbamazepine 100 µM 
(n = 10)
levetiracetam 100 µM 
(n = 11)
combination of all 3 drugs 
(n = 11)
Shortening amplitude (μm) −0.0174 ± 0.003 −0.0103 ± 0.0022 −0.0134 ± 0.0038 −0.0264 ± 0.0051
p < 0.0001 p < 0.001 p < 0.01 p < 0.001
Shortening velocity (μm/s) −0.778 ± 0.149 −0.3775 ± 0.2089 −0.6415 ± 0.277 −1.442 ± 0.269
p < 0.001 p > 0.05 p > 0.05 p < 0.0001
Relengthening velocity (μm/s) 0.4733 ± 0.1363 0.1414 ± 0.1183 0.4669 ± 0.204 0.9769 ± 0.248
p < 0.01 p > 0.05 p > 0.05 p < 0.01
Time to return to baseline 90% (ms) −0.727 ± 4.433 2.80 ± 4.08 2.727 ± 3.14   6.455 ± 2.695
p > 0.05 p > 0.05 p > 0.05 p > 0.05
p-Values are compared to the control condition (before application of the drug).
Significant p-values are highlighted in bold.
FigUre 3 | carbamazepine (cBZ), lamotrigine (lTg), and levetiracetam (leV) reversibly reduced shortening amplitudes. (a) Left panel shows original 
recording traces of one cell before, during and after wash-in of 100 µM LEV. The bar chart summarizes the significant and reversible reduction of shortening 
amplitudes of 11 cells, and the pie chart visualizes the efficacy of electromechanical coupling. (B) 100 µM CBZ (10 cells) also reduced significantly the shortening 
amplitude (bar chart) but did not influence excitation–shortening coupling (pie chart). (c) 100 µM LTG (11 cells) developed comparable effects as LEV and CBZ.
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study limitations and Translational Value 
of Our Findings for sUDeP in humans
People with epilepsy often display acquired or genetic alterations 
of voltage-gated ionic channels that are expressed in both heart 
and brain (6, 38). In the present study, however, we have tested 
the effects of three AEDs on the shortening properties of isolated 
cardiomyocytes of wild-type mice only, but not on cardiomyo-
cytes of mice with genetic or acquired epilepsy. In this context, 
it is of note that significant disturbances of electrical properties 
were found in cardiomyocytes of rodents with acquired or genetic 
epilepsies. For instance, the expression of NaV1.1 was increased 
in ventricular cardiomyocytes of a rat model of acquired epilepsy 
(kainic acid-induced status epilepticus model), leading to a 
prolonged duration of cardiac action potential and most likely 
to a prolongation of the QT interval (39). In a mouse model of 
Dravet syndrome, a severe form of childhood epilepsy with high 
mortality which is commonly caused by heterozygous muta-
tions in NaV1.1, ventricular myocytes surprisingly exhibited an 
increase in voltage-dependent sodium currents, probably due 
to an enhanced expression of NaV1.5 (40). These alterations 
were associated with an increased excitability, a prolongation of 
action potential duration, and an increase in triggered activity 
of cardiomyocytes in mice carrying the Dravet mutation. These 
two examples nicely illustrate possible modifications of cardiac 
FigUre 4 | lamotrigine (lTg) at higher concentrations and simultaneous application of carbamazepine (cBZ), lTg, and levetiracetam (leV) 
impaired electromechanical coupling. (a) Recording traces before, during, and after wash-in of 500 µM LTG upon continuous electrical stimulation at 4 Hz. Note 
that shortening amplitudes were greater if precedent stimulations failed to evoke a shortening (middle panel). (B) At 250 and 500 µM LTG, the excitation–shortening 
coupling was blocked in 62 and 100% of the cells, respectively. (c) Simultaneous application of all 3 antiepileptic drugs at 100 µM blocked electromechanical 
coupling in 8 of 19 cells (pie chart). In cells without faulty excitation–shortening coupling, shortening amplitudes were reduced by about 21%.
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properties at the level of gene expression in animal models of 
epilepsy but also demonstrate the difficulties in predicting poten-
tial consequences of such alterations for AED effects. A measur-
able effect on modulation of voltage-gated sodium currents by 
AED in cardiomyocytes of humans or animals with epilepsy, 
however, seems likely, given the differential sensitivities of splice 
variants and types of VGSC to AEDs (23, 41, 42). Thus, future 
studies are required to compare the effects of AEDs at different 
concentrations (including other AEDs than CBZ, LEV, and LTG) 
on cardiomyocytes of wild-type mice to those of mice with an 
epileptic phenotype.
Given these considerations, the translational value of our study 
for SUDEP in humans is rather limited. In view of the large spec-
trum of epilepsy-related cardiorespiratory alterations, SUDEP is 
likely to be a heterogeneous phenomenon and to have multiple 
etiologies (4, 5). Therefore, it appears plausible that in some cases, 
SUDEP is caused by fatal cardiac dysfunction due to myocardial 
failure, bradyarrhythmias, or ventricular tachyarrhythmias. Here, 
we have shown that CBZ, LEV, and LTG reversibly reduced the 
shortening of isolated wild-type cardiomyocytes and that LTG 
at higher concentrations or simultaneous application of all three 
AEDs blocked electromechanical coupling. Our findings may at 
least partially explain some of the cardiac disturbances, which 
were reported in epilepsy patients treated with AEDs in mono- or 
polytherapy. For instance, myocardial failure was reported in the 
context of CBZ intoxication (24, 43, 44), a complete atrioven-
tricular block upon an overdose of LTG (25) and occurrence of 
sinus node dysfunction, atrial flutter/fibrillation, atrioventricular 
block, or ventricular tachycardia in association with the combined 
use of sodium channel-blocking AEDs (34, 35, 45, 46).
In summary, our results suggest that rationale AED therapy 
may be important with respect to cardiac side effects and potential 
facilitation of serious cardiac dysfunction especially when AEDs 
are used in combination or at very high doses.
FigUre 5 | summary of antiepileptic drug (aeD) effects on shortening properties. (a) AEDs alone or in combination reduced shortening amplitudes by 
about 11–24%. (B) Only lamotrigine (LTG) at higher concentrations and simultaneous application of all three AEDs blocked excitation–shortening coupling. (c) The 
proportion between the number of failed stimulations (i.e., stimulation without subsequent shortening) and the total number of stimulations was defined as failure 
rate index. About 50% of the stimulations did not evoke shortenings in the presence of all three AEDs (COMB).
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